

Vitamin D status, body mass index, ethnicity and COVID-19: Initial analysis of the first-reported UK Biobank COVID-19 positive cases (n 580) compared with negative controls (n 723)

Andrea L. Darling¹, Kourosh R. Ahmadi¹, Kate A Ward², Nicholas C Harvey^{2,3}, Alexsander Couto Alves¹, Deborah K. Dunn-Walters¹, Susan A. Lanham-New¹, Cyrus Cooper²⁻⁴, David J. Blackbourn¹

Author affiliations:

1 School of Biosciences and Medicine, University of Surrey, Guildford. GU2 7XH

2 MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

3 NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, UK

4 NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK

In this short report we present a preliminary assessment of the serum 25-hydroxyvitamin D status (25(OH)D), body mass index (BMI), ethnicity and other lifestyle factors in the first-reported UK Biobank COVID-19 positive cases (n 580) compared with negative controls (n 723). The COVID-19 cases include those who have been treated as a hospital inpatient as well as those who have not, and are from England only. Mean (SD) for age was 57.5 (8.7) in positive cases and 57.9 (8.7) in negative controls.

Serum 25(OH)D status was almost identical in those who tested positive (median (Interquartile range, IQR)= 43.3 (32.1) nmol/L) compared to those who tested negative (median (IQR) 44.1 (31.2) nmol/L) for COVID-19. It must be borne in mind that the sample on average was not severely vitamin D deficient and results may differ in populations with a higher prevalence of severe vitamin D deficiency. As shown in Table 1, there was no difference in 25(OH)D status by gender; however 25(OH)D was significantly lower in those with obesity [P<0.001] by 9 nmol/L compared with those of normal or overweight. Of note, 25(OH)D status was also significantly lower in those of Asian, Black and Mixed ethnicity (by 16nmol/L) [P<0.001] compared with those of White ethnicity. This supports previous findings of a low serum 25(OH)D in UK South Asian individuals from the UK DFINES study¹.

Table 1: Serum 25(OH)D status by participant characteristic and COVID-19 test result

25(OH)D Median (IQR) nmol/L	Gender		Body Mass Index (BMI)			Ethnicity		Mann-Whitney/Kruskal Wallis test		
	Female	Male	Normal/under weight	Overweight	Obesity	Asian, Black, Mixed and Other	White	P for gender	P for BMI	P for ethnic
All	42.9 (31.7), n=590	44.1 (31.1), n=713	48.0 (32.4), n=378	47.0 (31.5), n=441	38.5 (28.4), n=468	30.0 (22.5), n=134	46.0 (31.5), n=1160	0.34	<0.001	<0.001
Cases (+ve)	41.7 (31.1), n=244	44.9 (32.3), n=336	47.1 (32.6), n=135	46.3 (31.3), n=208	38.6 (29.4), n=231	28.5 (22.2), n=81	46.0 (31.0), n=494	0.24	0.001	<0.001
Controls (-ve)	44.2 (32.4), n=346	43.6 (30.7), n=377	48.5 (31.7), n=243	47.5 (31.1), n=233	38.2 (27.1), n=237	32.3 (21.8), n=53	46.0 (31.4), n=666	0.81	<0.001	<0.001

A logistic regression model (Table 2) suggests that being overweight or obese; living in London; being male and being of Asian, Black or Mixed ethnicity is associated with a higher odds of testing positive for COVID-19, which confirms clinical observations which have been reported in the media.

Being a regular smoker (smoking on all or most days) was associated with a reduced odds (OR=0.58 (0.39-0.86)) of testing positive, compared with being a non-smoker (OR=1). However a key limitation of this analysis is that there were only a small number of regular smokers (n 142) and persons of Asian, Black or Mixed/Other Ethnicity in the sample and larger populations will be required to confirm these results.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Another limitation of our analysis is that vitamin D status was assessed in the UK Biobank cohort using baseline samples which were collected in 2006-2010. However, there is scientific evidence to show that that an individual's vitamin D

status tends to track over time; for example, those with status in the top quartile of 25(OH)D status in the population will likely still be in that range over a decade later². Therefore, we used quartiles of 25(OH)D status in our analysis rather than the specific 25(OH)D value which showed a null association with Covid-19 test result. When a BMI x 25(OH)D status (continuous variable) interaction term was trialed in the model, it was not statistically significant suggesting the interaction between BMI and 25(OH)D status did not predict test result in the currently available dataset.

Nevertheless, from our initial statistical model of the UK Biobank data, we can conclude a higher odds of testing positive for COVID-19 is associated with the cofactors of living in London; being male and being of Asian, Black or Mixed ethnicity.

As the number of reported cases increases in the UK Biobank, we will expand our model to control for additional factors such as blood pressure, use of statin medications, diagnoses of cardiovascular disease, respiratory disease, diabetes, COVID-19-attributed mortality and conditions affecting immune function, as well as genetics.

Table 2: Odds ratio of a positive COVID-19 test result- n=561 positive cases and n=705 negative controls- preliminary logistic regression model

Model P<0.001 Nagelkerke R Square=0.06	Participant n	Beta	Standard Error	P value	Odds ratio (OR)	95% C.I.for OR lower	95% C.I.for OR upper
Townsend Deprivation Index below median (lower deprivation)	646				1.00		
Townsend Deprivation Index above median (higher deprivation)	620	0.05	0.12	0.70	1.05	0.82	1.34
Region: England- Outside London	1031				1.00		
Region: England- London	235	0.37	0.16	0.02	1.45	1.05	2.00
Self-reported health: Excellent/good	734				1.00		
Self-reported health: Fair/poor	532	-0.13	0.12	0.29	0.88	0.69	1.12
BMI: Normal/Under weight	375				1.00		
BMI: Overweight	433	0.41	0.15	0.01	1.51	1.13	2.02
BMI: Obesity	458	0.52	0.15	0.00	1.67	1.24	2.26
Age category (Baseline age 40-60 y; currently 50-70y)	606				1.00		
Age category (Baseline age over 60y; currently over 70 y)	660	-0.25	0.12	0.04	0.78	0.62	0.99
Q1 25(OH)D Bottom 25%	314				1.00		
Q2 25(OH)D	317	-0.08	0.17	0.65	0.93	0.67	1.28
Q3 25(OH)D	314	0.03	0.17	0.84	1.03	0.74	1.44
Q4 (24(OH)D Top 25%	321	0.11	0.17	0.54	1.11	0.79	1.56
Ethnicity: White	1139				1.00		
Ethnicity: Asian, Black, Mixed and Other	127	0.51	0.22	0.02	1.66	1.08	2.54
Smoking: Non smoker	1080				1.00		
Smoking: Regular Smoker	142	-0.54	0.20	0.01	0.58	0.39	0.86
Smoking: Occasional	44	-0.19	0.32	0.56	0.83	0.44	1.56
Gender: Female	579				1.00		
Gender: Male	687	0.24	0.12	0.04	1.28	1.01	1.61
Constant		-0.61	0.19	0.00	0.55		

Variables in bold face are statistically significant based on 95% confidence intervals for OR. 25(OH)D= 25-hydroxyvitamin D (nmol/L). Q1=Quartile1, Q2= Quartile 2, Q3=Quartile 3, Q4=Quartile 4. y=years.

This research was conducted under UK Biobank Project 15168; the views are those of the authors' own. *Note: DKDW is not a collaborator on a UK Biobank project and did not view the data.*

References:

1 Darling AL, Hart KH, Macdonald HM, Horton K, Kang'ombe AR, Berry JL, Lanham-New SA. Vitamin D deficiency in UK South Asian Women of childbearing age: a comparative longitudinal investigation with UK Caucasian women. *Osteoporos Int*. 2013; **24**:477-88.

2 Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. *Am J Epidemiol*. 2010; **171**:903-8.

Author Potential Conflict of Interest:

CC reports consultancy, lecture fees and honoraria from AMGEN, GSK, Alliance for Better Bone Health, MSD, Eli Lilly, Pfizer, Novartis, Servier, Medtronic and Roche outside the scope of the submitted work. **NCH** reports consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Radius Health and Internis Pharma outside the scope of the submitted work. **SLN** reports honoraria for two conference talks from Thornton & Ross, consultancy for General Mills and is Research Director of D3Tex Ltd which holds the UK and GCC Patents for the use of UVB material for prevention of vitamin D deficiency. These are outside of the submitted work. **KAW** is a Royal Osteoporosis Society member of the Nutrition and Lifestyle Forum, American Society for Bone and Mineral Research Council member and International Osteoporosis Foundation member of the Committee for Scientific Advisors. All other authors report no conflict of interest.

Ethics:

The UK Biobank study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the UK North West Multi-centre Research Ethics Committee (MREC); application 11/NW/0382. Written informed consent was obtained from all subjects.

Financial Support:

This work was supported by in-house funds from the University of Surrey for payment of the UK Biobank access fee. The UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. UK Biobank is hosted by the University of Manchester and supported by the National Health Service (NHS). All the above funders had no role in the design, analysis or writing of the present study.